Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2928 in Advanced Solid Tumors and Hematological Malignancies
NCT04854681Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of tqb2928 in solid tumor (advanced stage) and hematological malignancies, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
tqb2928
03
Conditions
solid tumor (advanced stage)hematological malignancies
Beyond the preview
Go deeper on NCT04854681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854681.